Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open-Label, Multi-Center Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)

Next Previous
Trial Profile

A Phase 3, Open-Label, Multi-Center Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daxibotulinumtoxin A (Primary)
  • Indications Torticollis
  • Focus Adverse reactions; Registrational
  • Acronyms ASPEN-OLS
  • Sponsors Revance Therapeutics

Most Recent Events

  • 12 Apr 2024 According to a Revance Therapeutics media release, data assessing patient-desired retreatment intervals and examining the influence of the formulation of DAXXIFY on clinical performance, will be presented at the annual meeting of American Academy of Neurology (AAN), taking place April 13-18, 2024, in Denver, Colorado.
  • 14 Aug 2023 According to a Revance Therapeutics media release, United States (U.S.) Food and Drug Administration (FDA) has approved the first therapeutic indication for DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults.
  • 27 Apr 2023 Results of pooled analysis of two studies (ASPEN-1 & ASPEN-OLS) assessing efficacy, safety, and immunogenicity over multiple treatments of DaxibotulinumtoxinA for Injection in subjects with cervical dystonia, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top